Spero Therapeutics’ (SPRO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a report released on Thursday morning, Benzinga reports. They currently have a $7.00 price objective on the stock.

SPRO has been the subject of a number of other research reports. Cantor Fitzgerald restated an overweight rating on shares of Spero Therapeutics in a report on Tuesday, August 6th. TD Cowen upgraded Spero Therapeutics from a hold rating to a buy rating in a research report on Tuesday, August 6th.

Spero Therapeutics Trading Up 0.8 %

Spero Therapeutics stock opened at $1.30 on Thursday. Spero Therapeutics has a 12-month low of $0.99 and a 12-month high of $1.89. The firm has a 50-day moving average price of $1.32 and a 200-day moving average price of $1.44. The firm has a market capitalization of $70.19 million, a PE ratio of 3.02 and a beta of 0.62.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. Spero Therapeutics had a net margin of 14.74% and a return on equity of 25.67%. The business had revenue of $10.20 million during the quarter, compared to the consensus estimate of $9.80 million. During the same quarter last year, the firm earned ($0.23) earnings per share. As a group, sell-side analysts predict that Spero Therapeutics will post -1.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Spero Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Spero Therapeutics during the first quarter valued at approximately $31,000. Renaissance Technologies LLC increased its holdings in Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after purchasing an additional 121,492 shares during the period. Acadian Asset Management LLC raised its position in Spero Therapeutics by 121.8% during the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after purchasing an additional 418,742 shares in the last quarter. Murchinson Ltd. lifted its holdings in shares of Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after buying an additional 11,210 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Spero Therapeutics in the 4th quarter worth $1,570,000. 25.60% of the stock is currently owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.